Virological responses to atazanavir-ritonavir-based regimens: Resistance-substitutions score and pharmacokinetic parameters (Reyaphar study)

Antiviral Therapy

Volumn 11, Issue 4, 2006, Pages 421-429

  Pellegrin, Isabelle ^a   Breilh, Dominique ^a   Ragnaud, Jean Marie ^a   Boucher, Sébastien ^a   Neau, Didier ^a   Fleury, Hervé ^a   Schrive, Marie Hélène ^a   Saux, Marie Claude ^a   Pellegrin, Jean Luc ^a   Lazaro, Estibaliz ^a   Vray, Muriel ^b  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; EMTRICITABINE; ENFUVIRTIDE; LAMIVUDINE; LOPINAVIR; RITONAVIR; RNA; SAQUINAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; AMINO ACID SUBSTITUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ALGORITHMS; AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PYRIDINES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME;

EID: 33745792782     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Pellegrin I, Breilh D, Birac V, et al. Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens. Ther Drug Monit 2001; 23:332-340.
2. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS 2002; 16:1331-1340.
3. Marcelin AG, Lamotte C, Delaugerre C, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2003; 47:594-600.
4. Marcelin AG, Dalban C, Peytavin G, et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2004; 48:4687-4692.
5. Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR Study). AIDS 2004, 18:1305-1310.
6. Gong YF, Robinson BS, Rose RE, et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000; 44:2319-2326.
7. Colonno RJ, Thiry A, Limoli K, Parkin N. Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors. Antimicrob Agents Chemother 2003; 47:1324-1333.
8. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir-resistance mutation in treatment-naive HIV-1-infected patients receiving atazanavir-containing regimens. J Infect Dis 2004; 189:1802-1810
9. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS 2003; 17:2603-2614.
10. Squires KE, Thiry A, Giordano M. Atazanavir (ATV) QD and efavirenz (EFV) QD with fixed-dose ZDV+3TC: combination of antiviral efficacy and safety through W24 (AI424-034). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. September 2002, San Diego, CA, USA. Abstract M-1076.
11. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virofogical failures. AIDS 2005, 19:685-694.
12. Barrios A, Rendon AL, Gallego O, et al. Predictors of virological response to atazanavir in protease inhibitor-experienced patients. HIV Clin Trials 2004; 5:201-205.
13. Owen W, Chamberlain L, Warren D, et al. Safety and efficacy of antiretroviral treatment regimens containing tenofovir DF and atazanavir/ritonavir in HIV-infected adults. 3rd IAS Conference on HIV Pathogenesis and Treatment. July 2005, Rio de Janeiro, Brazil. Abstract WePe6.3C10.
14. Agarwala S, Russo R, Mummaneni V, Randall D, Geraldes M, O'Mara E. Steady-state pharmacokinetic (PK) interaction study of atazanavir (ATV) with ritonavir (RTV) in healthy subjects. 42nd Interscience Conference on Antimicrobial Agents & Chemotherapy. September 2002, San Diego, CA, USA. Abstract H-1716.
15. Bristol-Myers-Squibb Company. BMS-232632: Atazanavir Briefing Document. Hopewell, NJ: Bristol-Myers-Squibb; May 2003. [Accessed: 2004 July 23]. Available from: http://www.fda.gov/ohrms/dockets/
16. Colonno RJ, McLaren C, Kelleher T. Pathways to atazanavir resistance in treatment-experienced patients on atazanavir containing regimens. 2nd European HIV Drug Resistance. March 2004, Rome, Italy. Abstract 3.1.
17. Report 2004, under the direction of JF Delfraissy: Prise en charge thérapeutique des personnes infectées par le VIH, recommandations du groupe d'experts. Paris. Flammarion, Edition Medecine-Sciences. Available from: www.sante.gouv.fr
18. Vora S, Marcelin A, Günthard H, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor- experienced patients. AIDS 2006; 20: 35-40.
19. Pellegrin I, Vray M, Neau D, et al. Virological response to atazanavir/ritonavir-based regimens: resistance mutations score and pharmacokinetic parameters (Cmin, Cmax, AUC) (Reyaphar study). Antiviral Therapy 2005; 10 Suppl 1: S10.
20. Pellegrin I, Merel P, Garrigue I, et al. Comparison of capillary electrophoresis sequencing with the new CEQ3000 System (Beckman Coulter Inc) to conventional gel based systems for HIV-1 drug resistance analysis. J Virol Methods 2001; 98:9-16.
21. Johnson VA, Brun-Vezinet F, Clotet B, et al. Drug resistance mutations in HIV-1: 2005. Topics HIV Med 13:125-131.
22. Brun-Vézinet F, Costagliola D, Ait Khaled M, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antiviral Therapy 2004; 9:465-478.
23. Coakley EP, Mass MM, Chappey C & Parkin NT. Atazanavir (ATV) resistance in a protease inhibitor naïve patient treated with ATV/ritonavir associated with development of high-level ATV resistance and the N88S mutation in protease. 12th Conference of Retroviruses & Opportunistic Infections. February 2005, Boston, Mass., USA. Abstract 716.
24. Stanford University. HIV drug resistance database [cited 10 May 2006]. Available from: http://hivdb.stanford.edu/
25. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004; 48:2091-2096.
26. Gonzalez de Requena D, Bonora S, Canta F, et al. Atazanavir Cthough is associated with efficacy and safety: definition of therapeutic range. 12th Conference of Retroviruses and Opportunistic Infections. February 2005, Boston, Mass., USA. Abstract 645.
27. Kaul S, Bassi K, Damle B, et al. Pharmacokinetic (PK) evaluation of the combination of atazanavir (ATV) enteric coated didanosine (ddI-EC) and tenofovir disproxil fumarate (TDF) for a once-daily antiretroviral regimen. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. September 2003, Chicago, Ill., USA. Abstract A-1616.
28. Kearney BP, Mittan A, Sayre J, et al. Pharmacokinetic drug interaction and long term safety of tenofovir DF and lopinavir/ritonavir. 43rd Interscience Conference on Antimicrobial Agents & Chemotherapy. September 2003, Chicago, Ill., USA. Abstract A-1617.
29. Badaro R, DeJesus E, Lazzarin A, et al. Efficacy and safety of atazanavir (ATV) with ritonavir (RTV) versus lopinavir/ritonavir (LPV/RTV) in patients who have experienced virologic failure on multiple HAART regimens. 2nd IAS Conference on HIV Pathogenesis Treatment. July 2003. Paris, France. Abstract 118.